Black Diamond Therapeutics' CEO on the company's 'MasterKey' approach to precision oncology
Mark Velleca describes Black Diamond's 'MasterKey' approach to precision oncology that's aimed at solving many mutations at once, and updates us on lead programs targeting EGFR and BRAF.